Stockscreener 앱 받기
78.89
2.13%
-1.72
시간 외 거래:
78.89
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics Inc. (KYMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Eagle Health Investments LP Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
CCORF Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $106 - Moomoo
Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN
Which Is a Better Investment, Kymera Therapeutics, Inc. or Nurix Therapeutics, Inc. Stock? - AAII
Kymera presents KT-621 atopic dermatitis trial data at conferences - Investing.com UK
Kymera Therapeutics (KYMR) Valuation Check After New KT-621 And KT-579 Clinical And Preclinical Progress - Yahoo Finance
T. Rowe Price reports 5.46M-share stake in Kymera (KYMR) - Stock Titan
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses - Investing News Network
Kymera presents KT-621 atopic dermatitis trial data at conferences By Investing.com - Investing.com Nigeria
Wellington group holds 3.89M shares in Kymera (KYMR) — 4.76% stake - Stock Titan
Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses - marketscreener.com
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses - GlobeNewswire Inc.
Kymera Therapeutics stock (US50153V1061): Featured in psoriasis pipeline report - AD HOC NEWS
Why (KYMR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Kymera Therapeutics stock (US50153V1061): Director sells $261K in shares amid strong Q1 revenue - AD HOC NEWS
Law firm investigates Kymera Therapeutics for possible breach of fiduciary duties by directors - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire
Kymera Therapeutics director Elena Ridloff sells $261,000 in stock By Investing.com - Investing.com Australia
Kymera Therapeutics director Elena Ridloff sells $261,000 in stock - Investing.com
Kymera (KYMR) director Ridloff exercises options, sells 3,000 shares under 10b5-1 plan - Stock Titan
KYMR (KYMR) Form 144: 3,000-share sale; prior 10b5-1 sales disclosed - Stock Titan
Kymera Therapeutics stock (US50153V1061): Up after Q1 beat and new IBD data for KT-579 degrader cand - AD HOC NEWS
How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader Potential - Yahoo Finance
State of New Jersey Common Pension Fund D Makes New $2.61 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
CCORF Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $106 - Moomoo
FMR LLC holds 14.3% of Kymera Therapeutics (NASDAQ: KYMR) in 13G/A - Stock Titan
Kymera Therapeutics to Participate in Upcoming May Investor Conferences - Investing News Network
Kymera’s IRF5 degrader shows potential in IBD treatment - BioWorld News
Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Vanguard Group Inc. Buys 845,922 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
UBS Group AG Buys 88,314 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat
Kymera lines up two May investor webcasts from Las Vegas and New York - Stock Titan
Canaccord Genuity initiates coverage of Kymera Therapeutics (KYMR) with buy recommendation - MSN
Kymera presents preclinical data for IBD drug candidate KT-579 By Investing.com - Investing.com South Africa
Kymera presents preclinical data for IBD drug candidate KT-579 - Investing.com UK
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week - Investing News Network
Equities Analysts Issue Forecasts for KYMR Q2 Earnings - MarketBeat
Oral bowel disease drug matched approved therapies in preclinical tests - Stock Titan
Kymera Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-05-04 - Seeking Alpha
Kymera Therapeutics Q1 2026 earnings preview - MSN
Kymera Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq
H.C. Wainwright Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $134 - Moomoo
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
2.98%
1.33%
자본화:
|
볼륨(24시간):